Phosphate Binder Reduces FGF23 in CKD Patients
Patients with non-dialysis chronic kidney disease and iron deficiency anemia treated with ferric citrate experienced significant declines in FGF23 regardless of change in serum phosphorus.
Patients with non-dialysis chronic kidney disease and iron deficiency anemia treated with ferric citrate experienced significant declines in FGF23 regardless of change in serum phosphorus.
Even at very low levels, residual kidney function in hemodialysis patients clears uremic solutes.
From 1995 to 2015, the prevalence of hypertension and diabetes among patients starting hemodialysis increased from 67.9% to 87.6% and from 43.1% to 59.6%, respectively.
US veterans who underwent coronary artery bypass grafting versus percutaneous coronary intervention prior to starting dialysis had a 28% lower risk of death.
Study of U.S. veterans found that patients with resistant hypertension had 23%, 31%, and 144% higher risk of myocardial infarction, stroke, and end-stage renal disease, respectively.
Admission serum phosphorus levels below 2.5 and 4.9 mg/dL and above are associated with increased odds of dying in the hospital.
In a prospective study, mCRPC patients placed on enzalutamide after their disease progressed while on abiraterone therapy had a median radiographic progression-free survival of 8.1 months.
In a small but meaningful number of patients, Gleason pattern 4 disease missed by MRI and systematic biopsy is present outside the focal ablation zone.
New study may redefine the “stone belt” in the United States.
Physicians need a good understanding of a potential partner, regardless of the business model being considered.